Oncternal Therapeutics, Inc. (NASDAQ:ONCT – Get Free Report) was the recipient of a large decrease in short interest in December. As of December 31st, there was short interest totalling 13,100 shares, a decrease of 94.6% from the December 15th total of 241,400 shares. Approximately 0.4% of the shares of the company are short sold. Based […]
StockNews.com assumed coverage on shares of Oncternal Therapeutics (NASDAQ:ONCT – Free Report) in a research note published on Wednesday morning. The firm issued a sell rating on the stock. A number of other brokerages also recently issued reports on ONCT. HC Wainwright restated a buy rating and set a $40.00 price objective on shares of […]
StockNews.com assumed coverage on shares of Oncternal Therapeutics (NASDAQ:ONCT – Free Report) in a report released on Tuesday. The brokerage issued a sell rating on the stock. ONCT has been the subject of several other research reports. Brookline Capital Management upgraded Oncternal Therapeutics from a hold rating to a buy rating and set a $2.00 […]
StockNews.com started coverage on shares of Oncternal Therapeutics (NASDAQ:ONCT – Free Report) in a research note released on Tuesday morning. The firm issued a sell rating on the stock. Several other research analysts also recently weighed in on ONCT. Cantor Fitzgerald restated a neutral rating and set a $1.30 price objective on shares of Oncternal […]
HC Wainwright restated their buy rating on shares of Oncternal Therapeutics (NASDAQ:ONCT – Free Report) in a research report released on Wednesday morning, Benzinga reports. They currently have a $2.00 target price on the stock. A number of other equities analysts also recently commented on the company. Cantor Fitzgerald restated a neutral rating and set […]